Voyager Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Voyager Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, and proposes a significant increase in authorized common stock.
NASDAQ
DEFA14A: Voyager Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Voyager Therapeutics has scheduled its 2025 Annual Meeting for June 3, 2025, outlining proposals for stockholders to vote on, including the election of directors, executive compensation, and approval of stock incentive plans.
NASDAQ
Voyager Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on June 3, 2025, featuring proposals including director elections, executive compensation, auditor ratification, and stock incentive plan approvals.
NASDAQ
DEFA14A: Voyager Therapeutics Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
Voyager Therapeutics has scheduled its Annual Meeting for June 5, 2024, where stockholders will vote on director elections, executive compensation, and the ratification of the company's independent auditor.
NASDAQ
Voyager Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, to elect directors, approve executive compensation, and ratify the appointment of Ernst & Young LLP as its independent auditor.